Home > Healthcare > Drug Device Combination > Therapeutic Systems > Facial Palsy Market

Facial Palsy Market Trends

Report ID: GMI9166
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Facial Palsy Market Trends

Technological advancements in diagnostic imaging and surgical techniques are propelling innovation in the management of facial palsy. Enhanced imaging technologies, such as advanced electromyography, are facilitating more precise diagnosis.
State-of-the-art electromyography systems with high resolution that are extensively used in brain monitoring, providing increased sensitivity and spatial precision in facial palsy, enabling the accurate identification and localization of muscle activity. This has led the healthcare professionals to evaluate subtle muscle function changes and detect abnormalities with heightened precision.
Additionally, wireless electromyography systems have eliminated the necessity for bulky cables, offering enhanced flexibility in electrode placement and patient positioning. Consequently, the adoption of such advanced electromyography systems is increasing across diagnostic facilities, thereby driving the revenue growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of facial palsy reached USD 2.7 billion in 2023 and is set to witness 4.7% CAGR throughout 2032, owing to the increasing prevalence of facial paralysis, rising awareness for early screening and diagnosis.

The bell’s palsy segment accounted for a share of 72.7% in 2023, attributed to high incidence rate of bell’s palsy, increase in awareness for bell’s palsy treatment, and growing research focus for developing advanced therapeutics for the treatment of this condition.

North America market will reach USD 1.5 billion by 2032, due to the significant awareness for early diagnosis of facial palsy and its treatment, availability of advanced healthcare infrastructure in the region.

Brainlab AG (Dr. Langer Medical GmbH), GE Healthcare, GlaxoSmithKline plc, iTENS Australia, Johnson & Johnson Services, Inc., MED-EL Medical Electronics, Medtronic plc, Natus Medical, Nihon Kohden Corporation, Novartis AG, Pfizer Inc., Sanofi, Siemens Healthineers AG, TensCare Ltd, and Teva Pharmaceutical Industries Ltd.